Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus versus methylprednisolone for active thyroid eye disease
2023-510166-27-01Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Graves Orbitopathy (GO) comparing Sirolimus arm with Methylprednisolone arm (2 arms). Planned start Jun 2024; status: authorised.
02
Drugs
sirolimusmethylprednisolone
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-510166-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510166-27-01.